Cargando…
circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation
BACKGROUND: The BCR-ABL fusion protein is the key factor that results in the occurrence of chronic myeloid leukemia (CML). Imatinib (IM) is a targeted inhibitor of BCR-ABL to achieve complete remission. However, remission failure occurs due to acquired resistance caused by secondary BCR-ABL mutation...
Autores principales: | Wang, Jianming, Liang, Yang, Qin, Yuefeng, Jiang, Guoyun, Peng, Yuhang, Feng, Wenli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440867/ https://www.ncbi.nlm.nih.gov/pubmed/36058922 http://dx.doi.org/10.1186/s12967-022-03586-2 |
Ejemplares similares
-
Circular RNA circCRKL inhibits the proliferation of acute myeloid leukemia cells via the miR-196a-5p/miR-196b-5p/p27 axis
por: Liu, Wen, et al.
Publicado: (2021) -
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
por: Frietsch, Jochen J., et al.
Publicado: (2014) -
Domain organization differences explain Bcr-Abl’s preference for CrkL over CrkII
por: Jankowski, Wojciech, et al.
Publicado: (2012) -
Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL - An Alternative Approach to Conventional Rational Drug Design
por: Panigrahi, Soumya, et al.
Publicado: (2012) -
A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
por: Johnson, Kara J., et al.
Publicado: (2009)